Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta‐analysis of risk factors

Background Wide variations in revision endoscopic sinus surgery (ESS) rates for chronic rhinosinusitis with nasal polyposis (CRSwNP) have been reported. It is important to understand expected revision rates and factors that impact the need for revision. Methods A literature search was conducted on P...

Full description

Saved in:
Bibliographic Details
Published inInternational forum of allergy & rhinology Vol. 10; no. 2; pp. 199 - 207
Main Authors Loftus, Catherine A., Soler, Zachary M., Koochakzadeh, Sina, Desiato, Vincent M., Yoo, Frederick, Nguyen, Shaun A., Schlosser, Rodney J.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.02.2020
Subjects
Online AccessGet full text
ISSN2042-6976
2042-6984
2042-6984
DOI10.1002/alr.22487

Cover

More Information
Summary:Background Wide variations in revision endoscopic sinus surgery (ESS) rates for chronic rhinosinusitis with nasal polyposis (CRSwNP) have been reported. It is important to understand expected revision rates and factors that impact the need for revision. Methods A literature search was conducted on PubMed, Scopus, and the Cochrane Database of Systematic Reviews. Following PRISMA guidelines, a systematic review and meta‐analysis was performed on studies that reported revision surgery data for CRSwNP patients. Results Forty‐five studies with 34,220 subjects were meta‐analyzed, with an overall revision rate of 18.6% (95% confidence interval, 14.1%‐23.6%). Studies with extractable follow‐up data reported a mean revision rate of 16.2% over a weighted mean follow‐up of 89.6 months. Factors associated with increased revision rates included allergic fungal rhinosinusitis (28.7%), aspirin‐exacerbated respiratory disease (27.2%), asthma (22.6%), prior polypectomy (26.0%), and publication prior to 2008 (22.7%) (p < 0.05 for all). Conclusion Although polyps can recur after ESS, reported long‐term ESS revision rates are approximately 14% to 24%. Identifying risk factors for revision surgery can help manage patient expectations and determine optimal personalized treatments.
Bibliography:Presented orally at the Annual Meeting of the American Rhinologic Society, on September 13‐14, 2019, in New Orleans, LA.
Potential conflict of interest: Z.M.S.: Olympus, Optinose, Novartis, Regeneron, and Healthy Humming (not affiliated with this study), consultant; R.J.S.: Olympus, Arrinex, Optinose, Sanofi, and Healthy Humming (not affiliated with this study), consultant.
ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:2042-6976
2042-6984
2042-6984
DOI:10.1002/alr.22487